17-10-8　ⓔ文献

  1. Bennett JM, Catovsky D, et al: Proposals for the classification of the acute leukaemias. French–American–British (FAB) co–operative group. Br J Haematol, 1976; 33: 451–458.

  2. Jaffe EH, Harris NL, et al: World Health Organization classification of tumor: Pathology and genetics of tumors of heamtopoietic and lymphoid tissues, IARC press, 2001.

  3. Arber DA, Orazi A, et al: The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood, 2016; 127: 2391–2405.

  4. 松尾恵太郎：日本の造血器腫瘍の疫学．日本臨床，2007; 65: 9–13.

  5. Somasundaram R, Prasad MA, et al: Transcription factor networks in B–cell differentiation link development to acute lymphoid leukemia. Blood, 2015; 126: 144–152.

  6. Gu Z, Churchman ML, et al: PAX5–driven subtypes of B–progenitor acute lymphoblastic leukemia. Nat Genet, 2019; 51: 296–307.

  7. Belver L, Ferrando A: The genetics and mechanisms of T cell acute lymphoblastic leukaemia. Nat Rev Cancer, 2016; 16: 494–507.

  8. Ottmann OG, Pfeifer H: Management of Philadelphia chromosome–positive acute lymphoblastic leukemia (Ph+ ALL). Hematology Am Soc Hematol Educ Program, 2009; 371–381.

  9. Den Boer ML, van Slegtenhorst M, et al: A subtype of childhood acute lymphoblastic leukaemia with poor treatment outcome: a genome–wide classification study. Lancet Oncol, 2009; 10: 125–134.

  10. Pui CH, Evans WE: Treatment of acute lymphoblastic leukemia. N Engl J Med, 2006; 354: 166–178.

  11. van Dongen JJ, van der Velden VH, et al: Minimal residual disease diagnostics in acute lymphoblastic leukemia: need for sensitive, fast, and standardized technologies. Blood, 2015; 125: 3996–4009.

  12. Stock W, La M, et al: What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children’s Cancer Group and Cancer and Leukemia Group B studies. Blood, 2008; 112: 1646–1654.

  13. Short NJ, Kantarjian H, et al: SOHO state of the art update and next questions: Philadelphia chromosome–positive acute lymphoblastic leukemia. Clin Lymphoma Myeloma Leuk, 2018; 18: 439–446.

  14. Kantarjian H, Stein A, et al: Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med, 2017; 376: 836–847.

  15. Kantarjian HM, DeAngelo DJ, et al: Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long–term survival follow–up from the randomized, phase 3 INO-VATE study. Cancer, 2019; 125: 2474–2487.

  16. Maude SL, Laetsch TW, et al: Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med, 2018; 378: 439–448.

  17. Gokbuget N, Basara N, et al: High single–drug activity of nelarabine in relapsed T–lymphoblastic leukemia/lymphoma offers curative option with subsequent stem cell transplantation. Blood, 2011; 118: 3504–3511.

  18. Giebel S, Marks DI, et al: Hematopoietic stem cell transplantation for adults with Philadelphia chromosome–negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant, 2019; 54: 798–809.